Securities code: Shanghai Rightongene Biotechnology Co.Ltd(688217) securities abbreviation: Shanghai Rightongene Biotechnology Co.Ltd(688217) Announcement No.: 2022024 Shanghai Rightongene Biotechnology Co.Ltd(688217)
About directors, supervisors and senior managers in 2022
Announcement of salary scheme
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Shanghai Rightongene Biotechnology Co.Ltd(688217) (hereinafter referred to as “the company”) fully embodies the design requirements of combining short-term and long-term incentives and balancing individual and team interests in accordance with relevant laws and regulations and the articles of association, combined with the actual operation of the company and referring to the salary level of the industry and region; On the premise of protecting the interests of shareholders and realizing the common development of the company and the management, the company held four meetings of the second board of directors and four meetings of the second board of supervisors on April 18, 2022, which respectively deliberated and adopted the proposal on the remuneration scheme of directors in 2022, the proposal on the remuneration scheme of senior managers in 2022 and the proposal on the remuneration scheme of supervisors in 2022 The remuneration scheme of supervisors needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation. The remuneration plan for directors, supervisors and senior managers of the company in 2022 is as follows:
1、 Applicable objects of this scheme
Directors, supervisors and senior managers of the company in 2022
2、 Application period of this scheme
January 1, 2022 to December 31, 2022
3、 Specific content of salary scheme
(I) directors’ remuneration scheme
1. The independent directors of the company receive remuneration in the form of allowance, and the allowance standard is 80000 yuan / year (before tax). 2. If the company’s non independent directors hold positions in the company, they shall receive remuneration according to the specific positions they hold in the company and the relevant remuneration standards of the company and the performance appraisal of the current year; Non independent directors who do not hold office in the company will not receive remuneration.
(II) remuneration scheme for supervisors
Supervisors serving in the company will receive remuneration according to their specific management positions in the company, relevant remuneration standards of the company and performance appraisal of the current year, and will not receive supervisor allowance separately; Supervisors who do not hold office in the company will not receive remuneration in the company.
(III) remuneration scheme for senior managers
Senior managers in the company shall receive remuneration according to their specific management positions and relevant remuneration standards of the company and performance appraisal of the current year.
4、 Other provisions
1. The individual income tax involved in the above salary shall be uniformly withheld and paid by the company;
2. The salary can be adjusted appropriately according to the industry situation and the actual production and operation situation of the company;
3. If the directors, supervisors and senior managers of the company leave their posts due to change of office, re-election, resignation during their term of office, dismissal and other reasons, the remuneration shall be calculated and paid according to their actual term of office.
4. The company’s remuneration plan for directors and supervisors in 2022 needs to be submitted to the general meeting of shareholders for deliberation and approval before implementation. 5、 Opinions of independent directors
The independent directors of the company believe that the remuneration scheme of the directors and senior managers of the company takes full account of the company’s operation, the current industry and regional remuneration level, complies with the provisions of relevant laws and regulations and the articles of association, is conducive to the stable operation and long-term development of the company, and does not damage the interests of the company and shareholders, especially small and medium-sized shareholders.
We unanimously agree on the remuneration scheme of directors and senior managers, and agree to submit the remuneration scheme of directors to the 2021 annual general meeting of shareholders of the company for deliberation.
It is hereby announced.
Shanghai Rightongene Biotechnology Co.Ltd(688217) board of directors April 20, 2022
